Evaluating the Impact of Histologic Grade on Survival in Gallbladder Cancer

Abstract

year of diagnosis, and absense of LVI predicted for pCR. Using PSM in the subset of patients with adenocarcinoma, the rate of pCR was higher with 50.4 Gy vs. 41.4 Gy (HR 2.1 [95% CI 1.2 e 3.7], pZ0.01).There was no difference in pCR by dose for SCC. No differences in OS were identified between dose cohorts. The median OS increased to 63 mo with pCR vs 33 mo without (p<0.01). Conclusion: Utilization of 41.4 Gy for neoadjuvant CRT increased following publication of the CROSS trial, although rates remain low. 50.4 Gy was associated with higher pCR rate for esophageal adenocarcinoma compared to 41.4 Gy. Prospective studies will be needed to elucidate the optimal radiation dose in this setting.